Faisal Khurshid
Stock Analyst at Leerink Partners
(0.28)
# 4,043
Out of 4,759 analysts
15
Total ratings
16.67%
Success rate
-23.6%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.62 | +23.46% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $3.40 | +370.59% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $32.89 | +82.43% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $60.62 | +31.97% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $1.26 | +1,090.48% | 1 | Nov 4, 2024 | |
| TRVI Trevi Therapeutics | Assumes: Outperform | $7 | $4.30 | +62.79% | 1 | Sep 9, 2024 | |
| PRTC PureTech Health | Assumes: Outperform | $45 | $17.95 | +150.70% | 1 | Sep 9, 2024 | |
| IRWD Ironwood Pharmaceuticals | Initiates: Market Perform | $5 | $1.50 | +233.33% | 1 | Sep 9, 2024 | |
| GLPG Galapagos NV | Initiates: Market Perform | $24 | $26.58 | -9.71% | 1 | Sep 9, 2024 | |
| GERN Geron | Initiates: Outperform | $7 | $1.73 | +304.62% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $4.98 | +60.64% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $1.15 | +334.78% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $1.91 | +475.92% | 1 | Mar 21, 2023 |
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.62
Upside: +23.46%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $3.40
Upside: +370.59%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $32.89
Upside: +82.43%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $60.62
Upside: +31.97%
Zura Bio
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.26
Upside: +1,090.48%
Trevi Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $4.30
Upside: +62.79%
PureTech Health
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.95
Upside: +150.70%
Ironwood Pharmaceuticals
Sep 9, 2024
Initiates: Market Perform
Price Target: $5
Current: $1.50
Upside: +233.33%
Galapagos NV
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $26.58
Upside: -9.71%
Geron
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.73
Upside: +304.62%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $4.98
Upside: +60.64%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $1.15
Upside: +334.78%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $1.91
Upside: +475.92%